OVIT (OncoVista Innovative Therapies) EV-to-EBIT: -0.00 (As of Jul. 11, 2026)


What is OncoVista Innovative Therapies EV-to-EBIT?

OncoVista Innovative Therapies OVIT EV-to-EBIT is -0.00 as of Jul. 11, 2026.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, OncoVista Innovative Therapies's Enterprise Value is $0.00 Mil. OncoVista Innovative Therapies's EBIT for the trailing twelve months (TTM) ended in Sep. 2015 was $-3.26 Mil. Therefore, OncoVista Innovative Therapies's EV-to-EBIT for today is -0.00.

The historical rank and industry rank for OncoVista Innovative Therapies's EV-to-EBIT or its related term are showing as below:

OVIT's EV-to-EBIT is not ranked *
in the Biotechnology industry.
Industry Median: 15.02
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. OncoVista Innovative Therapies's Enterprise Value for the quarter that ended in Sep. 2015 was $10.31 Mil. OncoVista Innovative Therapies's EBIT for the trailing twelve months (TTM) ended in Sep. 2015 was $-3.26 Mil. OncoVista Innovative Therapies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2015 was -31.57%.

OncoVista Innovative Therapies  (OTCPK:OVIT) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

OncoVista Innovative Therapies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2015 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2015 ) =EBIT / Enterprise Value (Q: Sep. 2015 )
=-3.255/10.3104241
=-31.57 %

OncoVista Innovative Therapies's Enterprise Value for the quarter that ended in Sep. 2015 was $10.31 Mil.
OncoVista Innovative Therapies's EBIT for the trailing twelve months (TTM) ended in Sep. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoVista Innovative Therapies EV-to-EBIT Related Terms

OncoVista Innovative Therapies EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for OncoVista Innovative Therapies's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoVista Innovative Therapies EV-to-EBIT Chart

OncoVista Innovative Therapies Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.50 -2.50 -1.42 -0.68 -0.60

OncoVista Innovative Therapies Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.75 -0.60 -4.05 -7.62 -3.17

OVIT vs RSPI, HSTC, CAPS: EV-to-EBIT Comparison

For the Biotechnology subindustry, OncoVista Innovative Therapies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoVista Innovative Therapies EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoVista Innovative Therapies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where OncoVista Innovative Therapies's EV-to-EBIT falls into.


OncoVista Innovative Therapies EV-to-EBIT Calculation

OncoVista Innovative Therapies's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.002/-3.255
=-0.00

OncoVista Innovative Therapies's current Enterprise Value is $0.00 Mil.
OncoVista Innovative Therapies's EBIT for the trailing twelve months (TTM) ended in Sep. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-EBIT →
What does a EV-to-EBIT of -0.00 mean?
OncoVista Innovative Therapies (OVIT) has a EV-to-EBIT of -0.00 as of Jul. 11, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on OncoVista Innovative Therapies and its competitors.
Is OncoVista Innovative Therapies' EV-to-EBIT too high?
OncoVista Innovative Therapies' current EV-to-EBIT is -0.00.
How does OncoVista Innovative Therapies' EV-to-EBIT compare to RSPI and HSTC?
OncoVista Innovative Therapies' EV-to-EBIT of -0.00 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBIT is 15.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.02, based on 366 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on OncoVista Innovative Therapies and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OncoVista Innovative Therapies's current EV-to-EBIT is -0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoVista Innovative Therapies stock overvalued right now?
OncoVista Innovative Therapies (OVIT) has a current EV-to-EBIT of -0.00. The current EV-to-EBIT is -0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For OncoVista Innovative Therapies (OVIT), the current EV-to-EBIT is -0.00 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OncoVista Innovative Therapies Business Description

Address 14785 Omicron Drive, Suite 104, San Antonio, TX, USA, 78245
OncoVista Innovative Therapies Inc is a biopharmaceutical company. It is engaged in developing anticancer therapies by utilizing tumor-associated biomarkers.